ITT1505
ITT1505
- Catalog: ITT1505
- Gene/Protein: EIF2B3
- Product Description: Immunotag™ eIF2Bγ Polyclonal Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet | 
|
| Target Protein | EIF2Bγ |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,ELISA |
| Recommended Dilution | Western Blot: 1/500 - 1/2000. ELISA: 1/5000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse |
| Host Species | Rabbit |
| Immunogen | Synthesized peptide derived from eIF2Bγ . at AA range: 240-320 |
| Specificity | eIF2Bγ Polyclonal Antibody detects endogenous levels of eIF2Bγ protein. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
| Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Gene Name | EIF2B3 |
| Accession No. | Q9NR50 |
| Alternate Names | EIF2B3; Translation initiation factor eIF-2B subunit gamma; eIF-2B GDP-GTP exchange factor subunit gamma |
| Description | eukaryotic translation initiation factor 2B subunit gamma(EIF2B3) Homo sapiens The protein encoded by this gene is one of the subunits of initiation factor eIF2B, which catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP. It has also been found to function as a cofactor of hepatitis C virus internal ribosome entry site-mediated translation. Mutations in this gene have been associated with leukodystrophy with vanishing white matter. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2009], |
| Protein Expression | Blood,Hepatoma,Lymph node,Mammary gland, |
| Subcellular Localization | cytoplasm,cytosol,eukaryotic translation initiation factor 2B complex, |
| Protein Function | Experimental confirmation may be lacking for some isoforms,disease:Defects in EIF2B3 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.,function:Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.,similarity:Belongs to the EIF-2B gamma/epsilon subunits family.,subunit:Complex of five different subunits; alpha, beta, gamma, delta and epsilon., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|